Victoria Point, Australia

  • Chemical Debridement and Leg Ulcers

    A pilot study to investigate the relative effectiveness and safety of chemical wound debridement versus the curettage wound debridement in the treatment of venous and mixed aetiology leg ulcers in the United Kingdom

    Phase

    N/A

    Span

    45 weeks

    Sponsor

    DEBx Medical B.V.

    Eastbourne

    Recruiting

  • A Randomised Comparison of Left and Right Sided Approaches to Ablation of the Atrioventricular Junction

    Right-sided atrioventricular node ablation has been the initial conventional approach however up to 18.5% of patients require switching to a left sided approach or have a challenging procedure. Previous studies have found that left sided ablation is more efficacious than right-sided ablation requiring less than 5 applications of radiofrequency energy to induce atrioventricular block. This study will compare right sided atrioventricular node ablation to left sided atrioventricular node ablation

    Phase

    N/A

    Span

    105 weeks

    Sponsor

    East Sussex Hospitals NHS Trust

    Eastbourne, East Sussex

    Recruiting

  • A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test

    Phase

    N/A

    Span

    331 weeks

    Sponsor

    Hoffmann-La Roche

    Eastbourne

    Recruiting

  • Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

    1. Primary Objectives: a. To estimate real-world progression-free survival in patients with CLL who received acalabrutinib in the first-line. 2. Secondary Objectives: 1. To estimate real-world overall survival in patients with CLL who received acalabrutinib in the first-line. 2. To describe real-world response rate to acalabrutinib in patients with CLL who received acalabrutinib in the first-line. 3. To describe the healthcare resource utilisation in patients with CLL who received acalabrutinib in the first-line. 4. To describe post-progression treatment patterns in patients with CLL who progressed from first-line acalabrutinib. 5. To describe real-world clinical progression free survival in patients with CLL who received acalabrutinib in the first-line and progressed during acalabrutinib treatment. 6. To describe acalabrutinib treatment patterns in patients with CLL who received acalabrutinib in the first-line. 7. To describe baseline clinical and demographic characteristics in patients with CLL who received acalabrutinib in the first-line.

    Phase

    N/A

    Span

    233 weeks

    Sponsor

    AstraZeneca

    Eastbourne

    Recruiting

1-4 of 4